

Philippines

Population 2018

107 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	591 (332–924)	554 (311–866)
HIV-positive TB incidence	10 (4.1–19)	9.4 (3.8–17)
MDR/RR-TB incidence ^{oo}	18 (7.7–32)	17 (7.3–30)
HIV-negative TB mortality	26 (22–30)	24 (20–28)
HIV-positive TB mortality	0.6 (0–4.2)	0.57 (0–4)

Estimated proportion of TB cases with MDR/RR-TB, 2018	
New cases	1.7% (1.1–2.5)
Previously treated cases	16% (13–20)

TB case notifications, 2018	
Total new and relapse	371 668
- % tested with rapid diagnostics at time of diagnosis	36%
- % with known HIV status	27%
- % pulmonary	98%
- % bacteriologically confirmed ^{ooo}	36%
- % children aged 0–14 years	12%
- % women	30%
- % men	58%
Total cases notified	382 543

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2018	63% (40–110)
TB patients facing catastrophic total costs, 2017	35% (33–37)
TB case fatality ratio (estimated mortality/estimated incidence), 2018	5% (3–7)

TB/HIV care in new and relapse TB patients, 2018		
	Number	(%)
Patients with known HIV status who are HIV-positive	1 477	1%
- on antiretroviral therapy	1 350	91%

Drug-resistant TB care, 2018	
% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	<1%
- Previously treated cases	24%
Laboratory-confirmed cases*	MDR/RR-TB: 7 276, XDR-TB: 52
Patients started on treatment**	MDR/RR-TB: 6 125, XDR-TB: 52
MDR/RR-TB cases tested for resistance to second-line drugs	2 095

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2017	91%	315 923
Previously treated cases, excluding relapse, registered in 2017	82%	9 486
HIV-positive TB cases registered in 2017	83%	1 258
MDR/RR-TB cases started on second-line treatment in 2016	58%	5 071
XDR-TB cases started on second-line treatment in 2016	20%	10

TB preventive treatment, 2018	
% of HIV-positive people (newly enrolled in care) on preventive treatment	52%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	9.4% (8.7–10)

TB financing, 2019	
National TB budget (US\$ millions)	205
Funding source: 12% domestic, 25% international, 63% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically